Cell Chemical Biology 2018-03-22

Copper-Binding Small Molecule Induces Oxidative Stress and Cell-Cycle Arrest in Glioblastoma-Patient-Derived Cells

Kenichi Shimada, Eduard Reznik, Michael E. Stokes, Lakshmi Krishnamoorthy, Pieter H. Bos, Yuyu Song, Christine E. Quartararo, Nen C. Pagano, Darren R. Carpizo, Ana C. deCarvalho, Donald C. Lo, Brent R. Stockwell

Index: 10.1016/j.chembiol.2018.02.010

Full Text: HTML

Abstract

Transition metals are essential, but deregulation of their metabolism causes toxicity. Here, we report that the compound NSC319726 binds copper to induce oxidative stress and arrest glioblastoma-patient-derived cells at picomolar concentrations. Pharmacogenomic analysis suggested that NSC319726 and 65 other structural analogs exhibit lethality through metal binding. Although NSC319726 has been reported to function as a zinc ionophore, we report here that this compound binds to copper to arrest cell growth. We generated and validated pharmacogenomic predictions: copper toxicity was substantially inhibited by hypoxia, through an hypoxia-inducible-factor-1α-dependent pathway; copper-bound NSC319726 induced the generation of reactive oxygen species and depletion of deoxyribosyl purines, resulting in cell-cycle arrest. These results suggest that metal-induced DNA damage may be a consequence of exposure to some xenobiotics, therapeutic agents, as well as other causes of copper dysregulation, and reveal a potent mechanism for targeting glioblastomas.

Latest Articles:

Cellular Cyborgs: On the Precipice of a Drug Delivery Revolution

2018-04-05

[10.1016/j.chembiol.2018.03.003]

The Rheumatoid Arthritis-Associated Citrullinome

2018-04-05

[10.1016/j.chembiol.2018.03.002]

Dependence on the Pyrimidine Biosynthetic Enzyme DHODH Is a Synthetic Lethal Vulnerability in Mutant KRAS-Driven Cancers

2018-04-05

[10.1016/j.chembiol.2018.03.005]

The O-GlcNAc Transferase Intellectual Disability Mutation L254F Distorts the TPR Helix

2018-03-29

[10.1016/j.chembiol.2018.03.004]

Targeting Phosphopeptide Recognition by the Human BRCA1 Tandem BRCT Domain to Interrupt BRCA1-Dependent Signaling

2018-03-29

[10.1016/j.chembiol.2018.02.012]

More Articles...